Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
J Gen Virol
    May 2024
  1. AHRENS AK, Jonsson SR, Svansson V, Brugger B, et al
    Iceland: an underestimated hub for the spread of high-pathogenicity avian influenza viruses in the North Atlantic.
    J Gen Virol. 2024;105.
    >> Share

  2. KARA Y, Kizil MC, Iseri Nepesov M, Kacmaz E, et al
    Assessing the change in the epidemiology of seasonal respiratory viruses with the onset of the COVID-19 pandemic.
    J Gen Virol. 2024;105.
    >> Share

    February 2024
  3. HARDISTY G, Nicol MQ, Shaw DJ, Bennet ID, et al
    Latent gammaherpesvirus infection enhances type I IFN response and reduces virus spread in an influenza A virus co-infection model.
    J Gen Virol. 2024;105.
    >> Share

    January 2024
  4. HAYES RS, Oraby AK, Camargo C, Marchant DJ, et al
    Mapping respiratory syncytial virus fusion protein interactions with the receptor IGF1R and the impact of alanine-scanning mutagenesis on viral infection.
    J Gen Virol. 2024;105.
    >> Share

  5. SEEKINGS AH, Liang Y, Warren CJ, Hjulsager CK, et al
    Transmission dynamics and pathogenesis differ between pheasants and partridges infected with clade 2.3.4.4b H5N8 and H5N1 high-pathogenicity avian influenza viruses.
    J Gen Virol. 2024;105.
    >> Share

  6. MCMILLAN CLD, Wijesundara DK, Choo JJY, Amarilla AA, et al
    Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein.
    J Gen Virol. 2024;105.
    >> Share

    December 2023
  7. APAA T, Withers AJ, Mackenzie L, Staley C, et al
    Lack of detection of SARS-CoV-2 in British wildlife 2020-21 and first description of a stoat (Mustela erminea) Minacovirus.
    J Gen Virol. 2023;104.
    >> Share

    November 2023
  8. RANDALL RE, Young DF, Hughes DJ, Goodbourn S, et al
    Persistent paramyxovirus infections: in co-infections the parainfluenza virus type 5 persistent phenotype is dominant over the lytic phenotype.
    J Gen Virol. 2023;104.
    >> Share

  9. GRAND RJ
    SARS-CoV-2 and the DNA damage response.
    J Gen Virol. 2023;104.
    >> Share

    October 2023
  10. PHILIP AA, Hu S, Dai J, Patton JT, et al
    Recombinant rotavirus expressing the glycosylated S1 protein of SARS-CoV-2.
    J Gen Virol. 2023;104.
    >> Share

  11. UCHECHUKWU CF, Anyaduba UL, Udekwu CC, Orababa OQ, et al
    Desmoglein-2 and COVID-19 complications: insights into its role as a biomarker, pathogenesis and clinical implications.
    J Gen Virol. 2023;104.
    >> Share

  12. JUCKEL D, Desmarets L, Danneels A, Rouille Y, et al
    MERS-CoV and SARS-CoV-2 membrane proteins are modified with polylactosamine chains.
    J Gen Virol. 2023;104.
    >> Share

    July 2023
  13. THURSZ M, Sadiq F, Tree JA, Karayiannis P, et al
    Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
    J Gen Virol. 2023;104.
    >> Share

    June 2023
  14. OKUYA K, Khalil AM, Esaki M, Nishi N, et al
    Newly emerged genotypes of highly pathogenic H5N8 avian influenza viruses in Kagoshima prefecture, Japan during winter 2020/21.
    J Gen Virol. 2023;104.
    >> Share

  15. MIRABELLI C, Bragazzi Cunha J, Wotring JW, Sherman EJ, et al
    ARF6 is a host factor for SARS-CoV-2 infection in vitro.
    J Gen Virol. 2023;104.
    >> Share

  16. APAA T, Withers AJ, Staley C, Blanchard A, et al
    Sarbecoviruses of British horseshoe bats; sequence variation and epidemiology.
    J Gen Virol. 2023;104.
    >> Share

    May 2023
  17. JAMES J, Billington E, Warren CJ, De Sliva D, et al
    Clade 2.3.4.4b H5N1 high pathogenicity avian influenza virus (HPAIV) from the 2021/22 epizootic is highly duck adapted and poorly adapted to chickens.
    J Gen Virol. 2023;104.
    >> Share

  18. DE BUHR H, de Leeuw OS, Harders F, Peeters BP, et al
    Emergence of biased hypermutation in a heterologous additional transcription unit in recombinant lentogenic Newcastle disease virus.
    J Gen Virol. 2023;104.
    >> Share

  19. SULLIVAN DJ, Franchini M, Senefeld JW, Joyner MJ, et al
    Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
    J Gen Virol. 2023;104.
    >> Share

    April 2023
  20. SKOG E, Nykvist M, Naguib MM, Wille M, et al
    An oseltamivir-resistant avian H1N1 influenza A virus can transmit from mallards to chickens similarly to a wild-type strain: implications for the risk of resistance transmission to humans.
    J Gen Virol. 2023;104.
    >> Share

  21. WOO PCY, de Groot RJ, Haagmans B, Lau SKP, et al
    ICTV Virus Taxonomy Profile: Coronaviridae 2023.
    J Gen Virol. 2023;104.
    >> Share

    February 2023
  22. DANIELS RS, McCauley JW
    The health of influenza surveillance and pandemic preparedness in the wake of the COVID-19 pandemic.
    J Gen Virol. 2023;104.
    >> Share

  23. PURVES K, Haverty R, O'Neill T, Folan D, et al
    A novel antiviral formulation containing caprylic acid inhibits SARS-CoV-2 infection of a human bronchial epithelial cell model.
    J Gen Virol. 2023;104.
    >> Share

    November 2022
  24. ROY T, Sharma K, Dhall A, Patiyal S, et al
    In silico method for predicting infectious strains of influenza A virus from its genome and protein sequences.
    J Gen Virol. 2022;103.
    >> Share

  25. GRAND RJ
    A link between severe hepatitis in children and adenovirus 41 and adeno-associated virus 2 infections.
    J Gen Virol. 2022;103.
    >> Share

  26. DEMPSEY R, Ritter L, Parker L
    Strain development of A/H1N1pdm09 candidate vaccine viruses for the 2021-22 northern hemisphere influenza season.
    J Gen Virol. 2022;103.
    >> Share

  27. JAMES J, Byrne AMP, Goharriz H, Golding M, et al
    Infectious droplet exposure is an inefficient route for SARS-CoV-2 infection in the ferret model.
    J Gen Virol. 2022;103.
    >> Share

    July 2022
  28. SHARTOUNY JR, Lowen AC
    Message in a bottle: mRNA vaccination for influenza.
    J Gen Virol. 2022;103.
    >> Share

    June 2022
  29. LIU L, Weiss A, Saul VV, Schermuly RT, et al
    Comparative kinase activity profiling of pathogenic influenza A viruses reveals new anti- and pro-viral protein kinases.
    J Gen Virol. 2022;103.
    >> Share

    May 2022
  30. DE MOOR WRJ, Regnard GL, Rybicki EP, Williamson AL, et al
    Characterization of a dynamic self-replicating mammalian expression vector based on the circular ssDNA genome of beak and feather disease virus.
    J Gen Virol. 2022;103.
    >> Share

    April 2022
  31. THAKUR N, Gallo G, Newman J, Peacock TP, et al
    SARS-CoV-2 variants of concern alpha, beta, gamma and delta have extended ACE2 receptor host ranges.
    J Gen Virol. 2022;103.
    >> Share

    March 2022
  32. DOLINSKI AC, Homola JJ, Jankowski MD, Robinson JD, et al
    Differential gene expression reveals host factors for viral shedding variation in mallards (Anas platyrhynchos) infected with low-pathogenic avian influenza virus.
    J Gen Virol. 2022;103.
    >> Share

    November 2021
  33. SEALY JE, Howard WA, Molesti E, Iqbal M, et al
    Amino acid substitutions in the H5N1 avian influenza haemagglutinin alter pH of fusion and receptor binding to promote a highly pathogenic phenotype in chickens.
    J Gen Virol. 2021;102.
    >> Share

  34. ORR-BURKS N, Murray J, Todd KV, Bakre A, et al
    MicroRNAs affect GPCR and Ion channel genes needed for influenza replication.
    J Gen Virol. 2021;102.
    >> Share

  35. VIANA K, Zarpelon L, Leandro A, Terencio M, et al
    Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale.
    J Gen Virol. 2021;102.
    >> Share

  36. SZYMCZAK A, Jedruchniewicz N, Torelli A, Kaczmarzyk-Radka A, et al
    Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
    J Gen Virol. 2021;102.
    >> Share

    October 2021
  37. HUSSAIN S, Daniels RS, Wharton SA, Howell S, et al
    Reduced sialidase activity of influenza A(H3N2) neuraminidase associated with positively charged amino acid substitutions.
    J Gen Virol. 2021;102.
    >> Share

  38. MHAMDI Z, Carbonneau J, Venable MC, Baz M, et al
    Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.
    J Gen Virol. 2021;102.
    >> Share

  39. OLBRICH L, Castelletti N, Schalte Y, Gari M, et al
    Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2.
    J Gen Virol. 2021;102.
    >> Share

    September 2021
  40. STALLER E, Sheppard CM, Baillon L, Frise R, et al
    A natural variant in ANP32B impairs influenza virus replication in human cells.
    J Gen Virol. 2021;102.
    >> Share

    August 2021
  41. HIRST JC, Hutchinson EC
    Corrigendum: Single-particle measurements of filamentous influenza virions reveal damage induced by freezing.
    J Gen Virol. 2021;102.
    >> Share

  42. RAHMAN F, Libre C, Oleinikov A, Tcherniuk S, et al
    Chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A.
    J Gen Virol. 2021;102.
    >> Share

    July 2021
  43. POHL MO, Busnadiego I, Marrafino F, Wiedmer L, et al
    Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
    J Gen Virol. 2021;102.
    >> Share

    June 2021
  44. ELGENDY EM, Arai Y, Kawashita N, Isobe A, et al
    Double mutations in the H9N2 avian influenza virus PB2 gene act cooperatively to increase viral host adaptation and replication for human infections.
    J Gen Virol. 2021;102.
    >> Share

  45. CHAPPELL JG, Tsoleridis T, Clark G, Berry L, et al
    Retrospective screening of routine respiratory samples revealed undetected community transmission and missed intervention opportunities for SARS-CoV-2 in the United Kingdom.
    J Gen Virol. 2021;102.
    >> Share

    May 2021
  46. DISSANAYAKE TK, Yan B, Ng AC, Zhao H, et al
    Differential role of sphingomyelin in influenza virus, rhinovirus and SARS-CoV-2 infection of Calu-3 cells.
    J Gen Virol. 2021;102.
    >> Share

  47. GOLDEN JW, Zeng X, Cline CR, Garrison AR, et al
    Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease.
    J Gen Virol. 2021;102.
    >> Share

  48. ZHANG QY, Deng CL, Liu J, Li JQ, et al
    SARS-CoV-2 replicon for high-throughput antiviral screening.
    J Gen Virol. 2021;102.
    >> Share

    April 2021
  49. HENSS L, Auste A, Schurmann C, Schmidt C, et al
    The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
    J Gen Virol. 2021;102.
    >> Share

  50. SMITHER SJ, Eastaugh LS, Findlay JS, Laws TR, et al
    Investigative study into whether an insect repellent has virucidal activity against SARS-CoV-2.
    J Gen Virol. 2021;102.
    >> Share

  51. PEACOCK TP, Penrice-Randal R, Hiscox JA, Barclay WS, et al
    SARS-CoV-2 one year on: evidence for ongoing viral adaptation.
    J Gen Virol. 2021;102.
    >> Share

  52. DAVIES K, Buczkowski H, Welch SR, Green N, et al
    Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes.
    J Gen Virol. 2021;102.
    >> Share

    March 2021
  53. MONCHATRE-LEROY E, Lesellier S, Wasniewski M, Picard-Meyer E, et al
    Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2.
    J Gen Virol. 2021;102.
    >> Share

  54. GUPTA A, Sabarinathan R, Bala P, Donipadi V, et al
    A comprehensive profile of genomic variations in the SARS-CoV-2 isolates from the state of Telangana, India.
    J Gen Virol. 2021;102.
    >> Share

  55. ROE MK, Junod NA, Young AR, Beachboard DC, et al
    Targeting novel structural and functional features of coronavirus protease nsp5 (3CL(pro), M(pro)) in the age of COVID-19.
    J Gen Virol. 2021;102.
    >> Share

  56. AUERSWALD H, Yann S, Dul S, In S, et al
    Assessment of inactivation procedures for SARS-CoV-2.
    J Gen Virol. 2021;102.
    >> Share

  57. SIMMONDS P, Williams S, Harvala H
    Understanding the outcomes of COVID-19 - does the current model of an acute respiratory infection really fit?
    J Gen Virol. 2021;102.
    >> Share

    February 2021
  58. KHALIL AM, Yoshida R, Masatani T, Takada A, et al
    Variation in the HA antigenicity of A(H1N1)pdm09-related swine influenza viruses.
    J Gen Virol. 2021 Feb 22. doi: 10.1099/jgv.0.001569.
    >> Share

  59. CLEMENTS AL, Peacock TP, Sealy JE, Lee HM, et al
    PA-X is an avian virulence factor in H9N2 avian influenza virus.
    J Gen Virol. 2021 Feb 5. doi: 10.1099/jgv.0.001531.
    >> Share

    January 2021
  60. KIM DI, Cho YB, Lim Y, Hong SH, et al
    Chios mastic gum inhibits influenza A virus replication and viral pathogenicity.
    J Gen Virol. 2021 Jan 8. doi: 10.1099/jgv.0.001550.
    >> Share

  61. THAKUR N, Conceicao C, Isaacs A, Human S, et al
    Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.
    J Gen Virol. 2021;102.
    >> Share

    December 2020
  62. HARRIS M
    Microbiology Society online workshop on SARS-CoV-2 and COVID-19, Wednesday 29 July 2020.
    J Gen Virol. 2020;101:1227-1228.
    >> Share

    November 2020
  63. YU J, Li F, Wang D
    The first decade of research advances in influenza D virus.
    J Gen Virol. 2020 Nov 19. doi: 10.1099/jgv.0.001529.
    >> Share

  64. KLIMSTRA WB, Tilston-Lunel NL, Nambulli S, Boslett J, et al
    SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.
    J Gen Virol. 2020;101:1156-1169.
    >> Share

    October 2020
  65. LI Y, Chai W, Min J, Ye Z, et al
    Neddylation of M1 negatively regulates the replication of influenza A virus.
    J Gen Virol. 2020 Oct 5. doi: 10.1099/jgv.0.001503.
    >> Share

  66. FIRTH AE
    A putative new SARS-CoV protein, 3c, encoded in an ORF overlapping ORF3a.
    J Gen Virol. 2020;101:1085-1089.
    >> Share

  67. SILVA SJRD, Germano Mendes RP, Alves da Silva CT, Lorusso A, et al
    Insights into SARS-CoV-2, the Coronavirus Underlying COVID-19: Recent Genomic Data and the Development of Reverse Genetics Systems.
    J Gen Virol. 2020;101:1021-1024.
    >> Share

  68. RENNICK LJ, Nambulli S, Lemon K, Olinger GY, et al
    Recombinant subtype A and B human respiratory syncytial virus clinical isolates co-infect the respiratory tract of cotton rats.
    J Gen Virol. 2020;101:1056-1068.
    >> Share

  69. RIJSBERGEN LC, Rennick LJ, Laksono BM, van Run PRWA, et al
    In vivo comparison of a laboratory-adapted and clinical-isolate-based recombinant human respiratory syncytial virus.
    J Gen Virol. 2020;101:1037-1046.
    >> Share

    September 2020
  70. MOOIJ P, Mortier D, Stammes M, Fagrouch Z, et al
    Aerosolized pH1N1 influenza infection induces less systemic and local immune activation in the lung than combined intrabronchial, nasal and oral exposure in cynomolgus macaques.
    J Gen Virol. 2020 Sep 25. doi: 10.1099/jgv.0.001489.
    >> Share

  71. WANG J, Xu X, Zhou X, Chen P, et al
    Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.
    J Gen Virol. 2020;101:921-924.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016